Valeant Pharmaceuticals announced it has acquired the rights to Tasmar (tolcapone) in the US and certain non-European Union (EU) markets where it is currently sold from F. Hoffmann-La Roche (Roche) for $13.5 million in cash, plus royalties. The deal complements the company's acquisition strategy for growth in its key therapeutic areas.

Under the terms of the agreement, Valeant Pharmaceuticals acquires the rights to manufacture, market and distribute Tasmar in these countries. Manufacturing of the product will transition to Valeant over the next two years. Valeant will acquire and continue use of the Tasmar trademark.

Valeant Pharmaceuticals International is a global, publicly traded, research-based specialty pharmaceutical company that discovers, develops, manufactures and markets a broad range of pharmaceutical products.